Danielle P. Porter

TL;DR: Remdesivir (RDV) has superior anti-MERS activity in vitro and in vivo compared to combination therapy with lopinavir, ritonavir and interferon beta and reduces severe lung pathology.

TL;DR: The results collectively provide a unifying, refined mechanism of RDV-mediated RNA synthesis inhibition in coronaviruses and define this nucleotide analogue as a direct-acting antiviral.

TL;DR: The selectivity value for RDV-TP obtained here with a steady-state approach suggests that it is more efficiently incorporated than ATP and two other nucleotide analogs, which may explain the high potency of RDV against RNA viruses in cell-based assays.

TL;DR: The data support the early initiation of remdesivir treatment in patients with COVID-19 to prevent progression to pneumonia and reduce viral load and lung disease in a rhesus macaque model of SARS-CoV-2 infection.

TL;DR: Biochemical data indicate that the major contribution to EBOV RNA synthesis inhibition by remdesivir can be ascribed to delayed chain termination, and the long distance of five residues between the incorporated nucleotide analogue and its inhibitory effect warrant further investigation.